AJMC July 25, 2024
New FDA Approvals: ASCO Session Reviews Uses and Adverse Effects
What should doctors expect if they prescribe nirogacestat for desmoid tumors? What about fruquintinib for metastatic colorectal cancer (mCRC)?
Nirogacestat (Ogsiveo; Springworks Therapeutics) and fruquintinib (Fruzaqla; Takeda Pharmaceuticals) were among the therapies featured in the annual session on newly approved drugs, which took place on the first day of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
Mrinal M. Gounder, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, offered an overview of desmoid tumors, which are fibrous growths that emerge in connective tissue, typically in young adults. The tumors can appear in many areas of the body but most often are found in the abdomen. The experience can...
Today's Sponsors
Today's Sponsor